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The definition of ‘advanced’ hepatocellular carcinoma (HCC) 
has been vague and included various stages. This term has some-
times meant ‘multinodular/unresectable HCC’, ‘HCC with vas-
cular invasion’, or ‘HCC with extra-hepatic spread’. Since the in-
troduction of the Barcelona Clinic Liver Cancer (BCLC) stage in 
1999, the term ‘advanced HCC’ has been defined as a sympto-
matic tumor and/or invasive tumoral pattern (vascular invasion/ 
extrahepatic spread).
1 Based on data suggesting limited ef-
ficacy of cytotoxic systemic chemotherapy and results from the 
SHARP trial,
2,3 sorafenib, a multi-kinase inhibitor, is now the 
only drug which has been shown to prolong the survival of pa-
tients with HCC with vascular invasion or metastasis.
Transarterial chemoembolization (TACE) is the standard of 
care for patients with multinodular HCC.
4 Although there is not a 
standardized procedure with different embolic or chemotherapeutic 
agents,  different  arterial  selectivity  before  embolization,  or 
different schedules and indications for repeated sessions,
5 TACE 
has been shown to be effective in prolonging survival compared 
to supportive  care  in  randomized  controlled  trials  and 
meta-analyses.
5,6 However, the outcomes of TACE depend upon 
patient selection. In a randomized trial which recruited HCC 
patients with compensatory cirrhosis, good performance status, 
and large or multinodular HCC with neither portal vein invasion 
nor distant metastasis, the 2-year survival rate was 63% compared 
to 27% for the untreated control group (P=0.009).
7 In another 
randomized trial, inclusion of patients with symptoms or limited 
portal vein invasion resulted in a 2-year survival rate of 31%.
6 In 
a subgroup analysis, TACE offered no survival benefit in patients 
with portal vein invasion. In addition to high rates of tumor 
recurrence or progression after the procedure, TACE promotes 
vascular  endothelial  growth  factor  (VEGF)  production  and 
subsequent angiogenesis. Therefore, apart from adverse events, 
the  suboptimal anti-cancer  effects  of  TACE observed  when 
treating HCC with portal vein invasion may increase the chance 
of intra- or extra-hepatic spread of HCC.
Hepatic arterial infusional chemotherapy (HAIC) using low- 
or high-dose 5-FU and cisplatin for unresectable HCC has been 
established as a treatment option in Japan and several centers in 
South Korea. Despite several problems associated with HAIC 
such as subcutaneous port implantation and catheter placement, 
infection, and hepatic arterial occlusion with repeated therapies, 
promising HAIC anti-tumor effects without significant systemic 
adverse events have been reported in locally advanced HCC.
8,9      
In a Japanese study, low doses of 5-FU (170 mg/m
2 on day 1-5) 
and low doses of cisplatin (7 mg/m
2 on day 1-5) were infused 
through a subcutaneously-implanted port in HCC patients with 
portal vein thrombosis.
8 After four courses of monthly HAIC, 4 
(8.3%) and 19 (39.6%) out of 48 patients achieved complete 
response and partial response, respectively. In a Korean study in 
which high dose of 5-FU (500 mg/m
2 on day 1-3) and cisplatin 
(60 mg/m
2 on day) were administered, 9 (22.0%) and 14 (34.1%) 
patients exhibited a partial response and stable disease, 
respectively, without significant adverse events. The  overall 
survival time was significantly longer in the disease-controlled 
group  than  in  the  disease-progression group  (median  of  14 
versus 6 months, P <0.001).
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terms of efficacy between high- and low-dose regimens. A recent 
South Korean multicenter, randomized study showed that there 
was no significant difference in overall survival time (median of 
193 versus 153 days, P=0.108), although the objective response 
rate  was  improved  in  the  high-dose  group  compared  to  the 
low-dose group (16.7% versus 0%, P=0.024).
11 The presence of 
portal vein invasion without extra-hepatic spread is a clinical 
condition shared by repeated HAIC and systemic therapy using 
sorafenib.  However,  at  present  HAIC  may  not  be  generally 
recommended for treating advanced HCC because there has no 
randomized controlled study which shows a survival benefit of 
HAIC compared to sorafenib. Which transarterial therapy, then, 
is better for treating advanced HCC? A recent paper published 
by Kim et al. in The Korean Journal of Hepatology compared the 
treatment  outcomes  between  high-dose  HAIC  and  TACE  in 
cases of advanced HCC.
12 Thirty-six patients in HAIC group 
had been recruited for another multi-center, prospective trial and 
31 patients in TACE group were retrospectively selected from 
database of one institute. In this study, the objective responses 
(complete and partial responses) were significantly better in the 
group that underwent high-dose HAIC than in patients who 
received TACE (16.7% versus 0%, P=0.046). Overall survival 
was also better in the HAIC group compared to the TACE group 
(median  survival  times,  193  versus  87  days,  P=0.028).  The 
authors conclude that high-dose HAIC resulted in a better tumor 
response and survival outcome compared to conventional 
TACE using doxorubicin.
Strictly speaking, TACE and HAIC have different implications. 
Only  selected  cases  of  HCC  with  portal  vein  invasion  are 
amenable to TACE. On the contrary, HAIC had been developed 
for treating more advanced HCCs, such as cases with diffuse 
involvement of both lobes or main portal vein invasion, which 
cannot be treated with TACE. Despite retrospective matching of 
tumor  characteristics,  it  is  unclear  how  many  patients  had 
infiltrative  HCC,  bilobar  involvement,  and  main  portal  vein 
invasion  in  each  group.  Furthermore,  since  it  appeared  that 
gelfoam embolization had not been performed universally in the 
TACE group, actual comparison of HAIC and TACE in treating 
advanced HCC under the same tumor conditions might not have 
been done.
An important point of this study is that the effect of TACE 
monotherapy is a sub-optimal therapy for HCC with a substantial 
tumor burden, and so TACE is not beneficial in extensive (or 
diffusely involved) cases of HCC with or without portal vein 
invasion. For therapies for advanced HCC, we are armed with 
more  treatment  modalities  than  before.  Besides  HAIC,  the 
efficacy of multimodal approaches with external beam radiation 
therapy, internal  radiation with Yttrium-90, and combination 
therapies  using  sorafenib  and  other  treatments  for  advanced 
HCC need to be validated by well-designed studies.
13,14
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